<?xml version='1.0' encoding='utf-8'?>
<document id="27493481"><sentence text="Pharmacokinetic Interaction Study of Ranitidine and Daijokito in Healthy Volunteers."><entity charOffset="37-47" id="DDI-PubMed.27493481.s1.e0" text="Ranitidine" /></sentence><sentence text="Ranitidine is a histamine 2 receptor antagonist, and daijokito is a Kampo (Chinese herbal medicine as practiced in Japan) formula, which is traditionally used for treating constipation and digestive trouble"><entity charOffset="0-10" id="DDI-PubMed.27493481.s2.e0" text="Ranitidine" /><entity charOffset="16-25" id="DDI-PubMed.27493481.s2.e1" text="histamine" /><pair ddi="false" e1="DDI-PubMed.27493481.s2.e0" e2="DDI-PubMed.27493481.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27493481.s2.e0" e2="DDI-PubMed.27493481.s2.e1" /></sentence><sentence text=" Previous study demonstrated that daijokito significantly affected the pharmacokinetics of ranitidine in rats; however, the doses of ranitidine and daijokito in that study were higher than in clinical practice"><entity charOffset="91-101" id="DDI-PubMed.27493481.s3.e0" text="ranitidine" /><entity charOffset="133-143" id="DDI-PubMed.27493481.s3.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.27493481.s3.e0" e2="DDI-PubMed.27493481.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27493481.s3.e0" e2="DDI-PubMed.27493481.s3.e1" /></sentence><sentence text=" Therefore, we examined the pharmacokinetic interaction between ranitidine and daijokito in clinical practice doses in healthy volunteers"><entity charOffset="64-74" id="DDI-PubMed.27493481.s4.e0" text="ranitidine" /></sentence><sentence text="" /><sentence text="This was a randomized, open label, two-period crossover study in healthy volunteers (n = 7)" /><sentence text=" Volunteers received administrations of either a single dose of ranitidine 300 mg, or ranitidine 300 mg in combination with daijokito extract granules 2"><entity charOffset="64-74" id="DDI-PubMed.27493481.s7.e0" text="ranitidine" /><entity charOffset="86-96" id="DDI-PubMed.27493481.s7.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.27493481.s7.e0" e2="DDI-PubMed.27493481.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27493481.s7.e0" e2="DDI-PubMed.27493481.s7.e1" /></sentence><sentence text="5 g" /><sentence text=" Plasma concentrations of ranitidine were measured over 12 h by LC/MS/MS method"><entity charOffset="26-36" id="DDI-PubMed.27493481.s9.e0" text="ranitidine" /></sentence><sentence text="" /><sentence text="Plasma concentrations of ranitidine were lower with co-administration of daijokito compared with ranitidine alone"><entity charOffset="25-35" id="DDI-PubMed.27493481.s11.e0" text="ranitidine" /><entity charOffset="97-107" id="DDI-PubMed.27493481.s11.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.27493481.s11.e0" e2="DDI-PubMed.27493481.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27493481.s11.e0" e2="DDI-PubMed.27493481.s11.e1" /></sentence><sentence text=" Co-administration of daijokito significantly decreased ranitidine area under the plasma concentration-time curve from 0 to 12 h (AUC0-12) and maximum plasma concentration (Cmax) with geometric mean (GM) ratio [90% confidence interval (CI)] for AUC0-12 of 0"><entity charOffset="56-66" id="DDI-PubMed.27493481.s12.e0" text="ranitidine" /></sentence><sentence text="609 (0" /><sentence text="449, 0" /><sentence text="826) and Cmax of 0" /><sentence text="515 (0" /><sentence text="345, 0" /><sentence text="771)" /><sentence text="" /><sentence text="Co-administration of ranitidine with daijokito resulted in a significant decrease in plasma level of ranitidine in healthy volunteers"><entity charOffset="21-31" id="DDI-PubMed.27493481.s20.e0" text="ranitidine" /><entity charOffset="101-111" id="DDI-PubMed.27493481.s20.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.27493481.s20.e0" e2="DDI-PubMed.27493481.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27493481.s20.e0" e2="DDI-PubMed.27493481.s20.e1" /></sentence><sentence text="" /></document>